• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎感染中的心血管影响及治疗考量

Cardiovascular Implications and Therapeutic Considerations in COVID-19 Infection.

作者信息

Judson Gregory L, Kelemen Benjamin W, Njoroge Joyce N, Mahadevan Vaikom S

机构信息

Division of Cardiology, Department of Medicine, University of California, San Francisco, CA, USA.

出版信息

Cardiol Ther. 2020 Dec;9(2):293-305. doi: 10.1007/s40119-020-00184-5. Epub 2020 Jun 13.

DOI:10.1007/s40119-020-00184-5
PMID:32535752
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7292941/
Abstract

The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has profoundly impacted all fields of medicine. Infection with SARS-CoV-2 and the resulting coronavirus of 2019 (COVID-19) syndrome has multiorgan effects. The pandemic has united researchers from bench to bedside in attempts to understand the pathophysiology of the disease and define optimal treatment strategies. Cardiovascular disease is highly prevalent and a leading cause of death across gender, race, and ethnic groups. As the pandemic spreads, there is increasing concern about the cardiovascular effects of the viral infection and the interaction of infection with existing cardiovascular disease. Additionally, there are concerns about the cardiac effects of the numerous treatment agents under study. It will be essential for cardiologists to understand the interplay between underlying cardiac comorbidities, acute cardiovascular effects of COVID-19 disease, and adverse effects of new treatments. Here we describe emerging evidence of the epidemiology of SARS-CoV-2 infection and underlying cardiovascular disease, the evidence for direct myocardial injury in SARS-CoV-2 infection, the specific presentations of cardiovascular involvement by SARS-CoV-2, and the cardiac effects of emerging treatments.

摘要

目前正在肆虐的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)大流行对医学的各个领域都产生了深远影响。感染SARS-CoV-2以及由此引发的2019冠状病毒病(COVID-19)综合征具有多器官影响。这场大流行促使从实验室到临床的研究人员联合起来,试图了解该疾病的病理生理学并确定最佳治疗策略。心血管疾病非常普遍,是不同性别、种族和族裔群体的主要死因。随着大流行的蔓延,人们越来越关注病毒感染对心血管的影响以及感染与现有心血管疾病之间的相互作用。此外,人们还担心正在研究的众多治疗药物对心脏的影响。心脏病专家必须了解潜在的心脏合并症、COVID-19疾病的急性心血管影响以及新治疗方法的不良反应之间的相互作用。在此,我们描述了SARS-CoV-2感染和潜在心血管疾病流行病学的新证据、SARS-CoV-2感染中直接心肌损伤的证据、SARS-CoV-2心血管受累的具体表现以及新出现的治疗方法对心脏的影响。

相似文献

1
Cardiovascular Implications and Therapeutic Considerations in COVID-19 Infection.新型冠状病毒肺炎感染中的心血管影响及治疗考量
Cardiol Ther. 2020 Dec;9(2):293-305. doi: 10.1007/s40119-020-00184-5. Epub 2020 Jun 13.
2
Severe Acute Respiratory Syndrome by SARS-CoV-2 Infection or Other Etiologic Agents Among Brazilian Indigenous Population: An Observational Study from the First Year of Coronavirus Disease (COVID)-19 Pandemic.巴西原住民中由严重急性呼吸综合征冠状病毒2感染或其他病原体引起的严重急性呼吸综合征:一项关于冠状病毒病(COVID)-19大流行第一年的观察性研究。
Lancet Reg Health Am. 2022 Apr;8:100177. doi: 10.1016/j.lana.2021.100177. Epub 2022 Jan 7.
3
Cardiovascular Tropism and Sequelae of SARS-CoV-2 Infection.心血管亲嗜性与 SARS-CoV-2 感染的后遗症。
Viruses. 2022 May 25;14(6):1137. doi: 10.3390/v14061137.
4
Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).血管紧张素转化酶 2(ACE2)、严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)与 2019 冠状病毒病(COVID-19)的病理生理学。
J Pathol. 2020 Jul;251(3):228-248. doi: 10.1002/path.5471. Epub 2020 Jun 10.
5
Sex differences in the cardiac stress response following SARS-CoV-2 infection of ferrets.在雪貂感染 SARS-CoV-2 后,心脏应激反应的性别差异。
Am J Physiol Heart Circ Physiol. 2023 Nov 1;325(5):H1153-H1167. doi: 10.1152/ajpheart.00101.2023. Epub 2023 Sep 22.
6
Human and novel coronavirus infections in children: a review.儿童人感染和新型冠状病毒感染:综述。
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
7
An Insight Into Pathophysiology, Epidemiology, and Management of Cardiovascular Complications of SARS-CoV-2 Infection, Post-acute COVID Syndrome, and COVID Vaccine.深入了解 SARS-CoV-2 感染、新冠后综合征和 COVID 疫苗的心血管并发症的病理生理学、流行病学和管理。
Crit Pathw Cardiol. 2022 Sep 1;21(3):123-129. doi: 10.1097/HPC.0000000000000290. Epub 2022 Apr 28.
8
Myocardial injury and COVID-19: Possible mechanisms.心肌损伤与 COVID-19:可能的机制。
Life Sci. 2020 Jul 15;253:117723. doi: 10.1016/j.lfs.2020.117723. Epub 2020 Apr 28.
9
Can Epigenetics Help Solve the Puzzle Between Concomitant Cardiovascular Injury and Severity of Coronavirus Disease 2019?表观遗传学能否帮助解决 2019 年冠状病毒病伴随心血管损伤及其严重程度的难题?
J Cardiovasc Pharmacol. 2022 Apr 1;79(4):431-443. doi: 10.1097/FJC.0000000000001201.
10
Mechanics Insights of Alpha-Lipoic Acid against Cardiovascular Diseases during COVID-19 Infection.α-硫辛酸对抗 COVID-19 感染期间心血管疾病的作用机制。
Int J Mol Sci. 2021 Jul 26;22(15):7979. doi: 10.3390/ijms22157979.

引用本文的文献

1
Long-term effect of non-severe COVID-19 on pulmonary function, exercise capacities and physical activities: a cross-section study in Sakaka Aljouf.沙特阿吉兰省 Sakaka 地区非重症 COVID-19 对肺功能、运动能力和体力活动的长期影响:一项横断面研究。
F1000Res. 2024 Mar 4;12:809. doi: 10.12688/f1000research.133516.3. eCollection 2023.
2
An exploration of the characteristics of COVID-19 patients referred to a central cardiology hospital with acute coronary syndrome.探讨了因急性冠状动脉综合征被转诊至中心心脏病医院的 COVID-19 患者的特征。
Indian Heart J. 2022 Mar-Apr;74(2):135-138. doi: 10.1016/j.ihj.2021.12.013. Epub 2022 Jan 3.
3
Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129.心血管 RNA 标志物和人工智能可能改善 COVID-19 结局:来自 EU-CardioRNA COST 行动 CA17129 的立场文件。
Cardiovasc Res. 2021 Jul 7;117(8):1823-1840. doi: 10.1093/cvr/cvab094.
4
Cardiovascular Manifestations of COVID-19.新型冠状病毒肺炎的心血管表现
Heart Views. 2020 Jul-Sep;21(3):171-186. doi: 10.4103/HEARTVIEWS.HEARTVIEWS_150_20. Epub 2020 Oct 13.

本文引用的文献

1
At the Heart of the Matter: Unmasking and Addressing the Toll of COVID-19 on Diverse Populations.问题的核心:揭示并应对新冠疫情对不同人群造成的伤害。
Circulation. 2020 Jul 14;142(2):105-107. doi: 10.1161/CIRCULATIONAHA.120.048126. Epub 2020 May 4.
2
ST-Elevation Myocardial Infarction in Patients With COVID-19: Clinical and Angiographic Outcomes.新型冠状病毒肺炎患者的ST段抬高型心肌梗死:临床及血管造影结果
Circulation. 2020 Jun 23;141(25):2113-2116. doi: 10.1161/CIRCULATIONAHA.120.047525. Epub 2020 Apr 30.
3
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
4
Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Statement From the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP).《COVID-19 大流行期间急性心肌梗死的管理:心血管血管造影和介入学会(SCAI)、美国心脏病学会(ACC)和美国急诊医师学会(ACEP)的立场声明》
J Am Coll Cardiol. 2020 Sep 15;76(11):1375-1384. doi: 10.1016/j.jacc.2020.04.039. Epub 2020 Apr 21.
5
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.在纽约市地区,5700 名因 COVID-19 住院的患者的特征、合并症和结局。
JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775.
6
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.住院 COVID-19 合并高血压患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用率与死亡率的关系。
Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17.
7
ST-Segment Elevation in Patients with Covid-19 - A Case Series.新型冠状病毒肺炎患者的ST段抬高——病例系列
N Engl J Med. 2020 Jun 18;382(25):2478-2480. doi: 10.1056/NEJMc2009020. Epub 2020 Apr 17.
8
Clinical Characteristics of Covid-19 in New York City.纽约市新冠肺炎的临床特征
N Engl J Med. 2020 Jun 11;382(24):2372-2374. doi: 10.1056/NEJMc2010419. Epub 2020 Apr 17.
9
Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020.2020 年 3 月 1 日至 30 日,14 个州住院的经实验室确诊的 2019 冠状病毒病患者的住院率和特征 - COVID-NET。
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464. doi: 10.15585/mmwr.mm6915e3.
10
Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome.急性 COVID-19 心血管综合征的描述与处理建议。
Circulation. 2020 Jun 9;141(23):1903-1914. doi: 10.1161/CIRCULATIONAHA.120.047349. Epub 2020 Apr 16.